References
- Kaur G, Narang RK, Rath G, et al. Advances in pulmonary delivery of nanoparticles. Artif Cells Nanomed Biotechnol. 2011;2:75–96.
- Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest. 2007;117:524–529.
- Zisman DA, Keane MP, Belperio JA, et al. Pulmonary fibrosis. Methods Mol Med. 2005;117:3–44.
- Liu RM, Desai LP. Reciprocal regulation of TGF-β and reactive oxygen species: a perverse cycle for fibrosis. Redox Biol. 2015;6:565–577.
- Warburton D, Shi W, Xu B. TGF-β-Smad3 signaling in emphysema and pulmonary fibrosis: an epigenetic aberration of normal development? Am J Physiol Lung Cell Mol Physiol. 2013;304:L83–L85.
- Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med. 2001;345:517–525.
- Lee CM, Park JW, Cho WK, et al. Modifiers of TGF-β1 effector function as novel therapeutic targets of pulmonary fibrosis. Korean J Intern Med. 2014;29:281–290.
- Conte E, Fagone E, Gili E, et al. Preventive and therapeutic effects of Thymosin beta4 N-terminal fragment Ac-SDKP in the bleomycin model of pulmonary fibrosis. Oncotarget. 2016;7:33841–33854.
- Oh K, Seo MW, Kim YW, et al. Osteopontin potentiates pulmonary inflammation and fibrosis by modulating IL-17/IFN-gamma-secreting T-cell Ratios in bleomycin-treated mice. Immune Netw. 2015;15:142–149.
- Rice KM, Manne N, Kolli MB, et al. Curcumin nanoparticles attenuate cardiac remodeling due to pulmonary arterial hypertension. Artif Cells Nanomed Biotechnol. 2015;03:1909–1916.
- Kolb M, Margetts PJ, Anthony DC, et al. Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. J Clin Invest. 2001;107:1529–1536.
- Wilson MS, Wynn TA. Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal Immunol. 2009;2:103–121.
- Joshi BH, Hogaboam C, Dover P, et al. Role of interleukin-13 in cancer, pulmonary fibrosis, and other T(H)2-type diseases. Vitam Horm. 2006;74:479–504.
- Yao Z, Spriggs MK, Derry JM, et al. Molecular characterization of the human interleukin (IL)-17 receptor. Cytokine. 1997;9:794–800.
- Chen XL, Li WB, Zhou AM, et al. Role of endogenous peroxynitrite in pulmonary injury and fibrosis induced by bleomycin A5 in rats. Acta Pharmacol Sin. 2003;24:697–702.
- Shi K, Jiang J, Ma T, et al. Dexamethasone attenuates bleomycin-induced lung fibrosis in mice through TGF-β, Smad3 and JAK-STAT pathway. Int J Clin Exp Med. 2014;7:2645–2650.
- Adamson IY, Bowden DH. The pathogenesis of bleomycin-induced pulmonary fibrosis in mice. Am J Pathol. 1974;77:185–197.
- Szapiel SV, Elson NA, Fulmer JD, et al. Bleomycin-induced interstitial pulmonary disease in the nude, athymic mouse. Am Rev Respir Dis. 1979;120:893–899.
- Shoki AH, Mayer-Hamblett N, Wilcox PG, et al. Systematic review of blood biomarkers in cystic fibrosis pulmonary exacerbations. Chest. 2013;144:1659–1670.
- Molet S, Hamid Q, Davoine F, et al. IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J Allergy Clin Immunol. 2001;108:430–438.
- Chen X, Vodanovic-Jankovic S, Johnson B, et al. Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. Blood. 2007;110:3804–3813.
- Rath G, Hussain T, Chauhan G, et al. Fabrication and characterization of cefazolin-loaded nanofibrous mats for the recovery of post-surgical wound. Artif Cells Nanomed Biotechnol. 2015;18:1783–1792.
- Tan HL, Rosenthal M. IL-17 in lung disease: friend or foe? Thorax. 2013;68:788–790.